Department of Nephrology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia; Department of Medicine - Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia.
Department of Nephrology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia; Department of Medicine - Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia.
Bone. 2018 May;110:355-367. doi: 10.1016/j.bone.2018.02.023. Epub 2018 Feb 27.
Calciprotein particles (CPP) have emerged as nanoscale mediators of phosphate-induced toxicity in Chronic Kidney Disease (CKD). Uraemia favors ripening of the particle mineral content from the amorphous (CPP-I) to the crystalline state (CPP-II) but the pathophysiological significance of this transformation is uncertain. Clinical studies suggest an association between CPP ripening and inflammation, vascular dysfunction and mortality. Although ripening has been modelled in vitro, it is unknown whether particles synthesised in serum resemble their in vivo counterparts. Here we show that in vitro formation and ripening of CPP in uraemic serum is characterised by extensive physiochemical rearrangements involving the accretion of mineral, loss of surface charge and transformation of the mineral phase from a spherical arrangement of diffuse domains of amorphous calcium phosphate to densely-packed lamellar aggregates of crystalline hydroxyapatite. These physiochemical changes were paralleled by enrichment with small soluble apolipoproteins, complement factors and the binding of fatty acids. In comparison, endogenous CPP represent a highly heterogeneous mixture of particles with characteristics mostly intermediate to synthetic CPP-I and CPP-II, but are also uniquely enriched for carbonate-substituted apatite, DNA fragments, small RNA and microbe-derived components. Pathway analysis of protein enrichment predicted the activation of cell death and pro-inflammatory processes by endogenous CPP and synthetic CPP-II alike. This comprehensive characterisation validates the use of CPP-II generated in uraemic serum as in vitro equivalents of their endogenous counterparts and provides insight into the nature and pathological significance of CPP in CKD, which may act as vehicles for various bioactive ligands.
钙磷蛋白颗粒 (CPP) 已成为慢性肾脏病 (CKD) 中磷诱导毒性的纳米级介质。尿毒症有利于 CPP 颗粒中矿物成分从无定形 (CPP-I) 向结晶状态 (CPP-II) 的成熟,但这种转化的病理生理意义尚不确定。临床研究表明 CPP 成熟与炎症、血管功能障碍和死亡率之间存在关联。虽然 CPP 的成熟已在体外进行建模,但尚不清楚血清中合成的颗粒是否与体内的 CPP 相似。在这里,我们表明 CPP 在尿毒症血清中的体外形成和成熟伴随着广泛的物理化学重排,涉及矿物的积累、表面电荷的损失以及矿物相的转变,从无定形磷酸钙的弥散域的球形排列转变为密集堆积的羟磷灰石层状聚集体。这些物理化学变化伴随着小可溶性载脂蛋白、补体因子和脂肪酸的富集。相比之下,内源性 CPP 代表了一种高度异质的颗粒混合物,其特征大多介于合成 CPP-I 和 CPP-II 之间,但也特别富含碳酸取代的磷灰石、DNA 片段、小 RNA 和微生物衍生的成分。蛋白质富集的途径分析预测了内源性 CPP 和合成 CPP-II 都能激活细胞死亡和促炎过程。这种全面的特征验证了使用尿毒症血清中生成的 CPP-II 作为其内源性对应物的体外等效物,并深入了解了 CPP 在 CKD 中的性质和病理生理意义,CPP 可能作为各种生物活性配体的载体。